Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Payables (2022 - 2025)

Historic Payables for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Entrada Therapeutics' Payables rose 14504.64% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 14504.64%. This contributed to the annual value of $4.3 million for FY2024, which is 2996.64% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Payables is $3.2 million, which was up 14504.64% from $1.9 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Payables high stood at $6.5 million for Q1 2023, and its period low was $752000.0 during Q3 2023.
  • Moreover, its 4-year median value for Payables was $2.5 million (2024), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Payables crashed by 6096.69% in 2024, and later skyrocketed by 14504.64% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Payables stood at $6.0 million in 2022, then crashed by 45.29% to $3.3 million in 2023, then rose by 29.97% to $4.3 million in 2024, then dropped by 25.66% to $3.2 million in 2025.
  • Its Payables was $3.2 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.2 million in Q1 2025.